IS8267A - [1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa - Google Patents

[1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa

Info

Publication number: IS8267A
Authority: IS; Iceland
Prior art keywords: naphthyridin; schizophrenia; treatment; related compounds; compounds
Prior art date: 2003-08-22

Application number

IS8267A

Other languages

English (en)

Inventor

Clark Jerry

Davis Jamie

Favor David

Fay Lorraine

Franklin Lloyd

Henegar Kevin

Johnson Douglas

Nichelson Brian

Ou Ligong

Thomas Repine Joseph

Walters Michael

David White Andrew

Zhu Zhijian

Original Assignee

Warner-Lambert Company Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-22

Filing date

2006-01-26

Publication date

2006-01-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34216117&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8267(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-01-26 Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc

2006-01-26 Publication of IS8267A publication Critical patent/IS8267A/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Ophthalmology & Optometry (AREA)
Psychology (AREA)
Virology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Hospice & Palliative Care (AREA)
Pain & Pain Management (AREA)
Anesthesiology (AREA)
AIDS & HIV (AREA)
Oncology (AREA)
Child & Adolescent Psychology (AREA)
Nutrition Science (AREA)
Obesity (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

IS8267A 2003-08-22 2006-01-26 [1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa IS8267A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US49737003P	2003-08-22	2003-08-22
PCT/IB2004/002665 WO2005019215A1 (en)	2003-08-22	2004-08-13	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

Publications (1)

Publication Number	Publication Date
IS8267A true IS8267A (is)	2006-01-26

Family

ID=34216117

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8267A IS8267A (is)	2003-08-22	2006-01-26	[1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa

Country Status (35)

Country	Link
US (3)	US7160888B2 (is)
EP (1)	EP1660497A1 (is)
JP (1)	JP4034811B2 (is)
KR (2)	KR100801794B1 (is)
CN (1)	CN100422181C (is)
AP (1)	AP2006003525A0 (is)
AR (1)	AR045386A1 (is)
AU (1)	AU2004266191B2 (is)
BR (1)	BRPI0413860A (is)
CA (1)	CA2538915C (is)
CR (2)	CR8254A (is)
CU (1)	CU23464B7 (is)
EA (1)	EA009645B1 (is)
EC (1)	ECSP066391A (is)
GE (1)	GEP20084447B (is)
GT (1)	GT200500007A (is)
HN (1)	HN2004000319A (is)
IL (1)	IL173439A0 (is)
IS (1)	IS8267A (is)
MA (1)	MA28003A1 (is)
ME (1)	MEP45308A (is)
MX (1)	MXPA06002070A (is)
MY (1)	MY140693A (is)
NL (1)	NL1026892C2 (is)
NO (1)	NO20060324L (is)
NZ (1)	NZ545078A (is)
OA (1)	OA13238A (is)
PA (1)	PA8609701A1 (is)
PE (1)	PE20051039A1 (is)
RS (1)	RS20060129A (is)
TN (1)	TNSN06063A1 (is)
TW (1)	TWI298327B (is)
UA (1)	UA82541C2 (is)
WO (1)	WO2005019215A1 (is)
ZA (1)	ZA200601526B (is)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE9904723D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission II
SE9904724D0 (sv)	1999-12-22	1999-12-22	Carlsson A Research Ab	New modulators of dopamine neurotransmission I
USRE46117E1 (en)	1999-12-22	2016-08-23	Teva Pharmaceuticals International Gmbh	Modulators of dopamine neurotransmission
WO2003007956A1 (en)	2001-07-20	2003-01-30	Psychogenics, Inc.	Treatment for attention-deficit hyperactivity disorder
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
KR101245075B1 (ko)	2004-06-08	2013-03-18	엔에스아베 필리알 아프 뉴로서치 스웨덴 아베 스베리게	도파민 신경전달의 모듈레이터로서 신 2기치환된페닐피페리딘/피페라진
AU2005251909A1 (en) *	2004-06-08	2005-12-22	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	New disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
US7851629B2 (en)	2004-06-08	2010-12-14	Nsab, Filial Af Neurosearch Sweden Ab, Sverige	Disubstituted phenylpiperidines as modulators of dopamine and serotonin neurotransmission
AU2005293754B2 (en)	2004-10-13	2011-07-21	Teva Pharmaceuticals International Gmbh	Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-N-propyl-piperidine
FR2877005A1 (fr) *	2004-10-22	2006-04-28	Bioprojet Soc Civ Ile	Nouveaux derives d'arylpiperazine
WO2006081289A2 (en)	2005-01-25	2006-08-03	Glaxo Group Limited	Antibacterial agents
WO2006090273A2 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds with keto or hydroxyl linkers for the treatment of schizophrenia
WO2006090272A1 (en) *	2005-02-22	2006-08-31	Warner-Lambert Company Llc	Isoquinoline [1,8]naphthyridin-2-ones and related compounds for treatment of schizophrenia
AU2006228426A1 (en) *	2005-04-01	2006-10-05	Warner-Lambert Company Llc	Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
UA88518C2 (ru) *	2005-04-08	2009-10-26	Пфайзер Продактс Инк.	Бицикло[3,1,0]гетероариламиды как ингибиторы транспорта глицина типа i
JP4315393B2 (ja) *	2005-04-14	2009-08-19	大塚製薬株式会社	複素環化合物
RU2402549C3 (ru) *	2005-04-14	2022-03-10	Оцука Фармасьютикал Ко., Лтд.	Пиперазин-замещенные бензотиофены для лечения психических расстройств
TWI320783B (en) *	2005-04-14	2010-02-21	Otsuka Pharma Co Ltd	Heterocyclic compound
TWI329641B (en)	2005-08-31	2010-09-01	Otsuka Pharma Co Ltd	(benzo[b]thiophen-4-yl)piperazine compounds, pharmaceutical compositions comprising the same, uses of the same and processes for preparing the same
JP5480503B2 (ja)	2005-10-07	2014-04-23	エクセリクシス，インク．	ＰＩ３Ｋαのピリドピリミジノン型阻害剤
SE529246C2 (sv)	2005-10-13	2007-06-12	Neurosearch Sweden Ab	Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission
CA2627779A1 (en) *	2005-10-31	2007-05-10	Pfizer Products Inc.	Crystalline salts of 7-[4-(4-naphthalen-1-yl-piperazin-1-yl)-butoxy]-3,4-dihydro-1h-[1,8]naphthyridin-2-one
EP1988077A4 (en)	2006-02-23	2009-09-02	Shionogi & Co	NUCLEIC HETEROCYCLIC DERIVATIVES SUBSTITUTED BY CYCLIC GROUPS
WO2007116265A1 (en) *	2006-03-31	2007-10-18	Pfizer Products Inc.	Process for making a tetrahydro-pyridoazepin-8-one compound
CA2651732C (en)	2006-05-18	2014-10-14	Mannkind Corporation	Intracellular kinase inhibitors
HRP20110621T2 (hr) *	2006-09-15	2013-12-06	Pfizer Products Inc.	SPOJEVI PIRIDO[2,3-d]PIRIMIDINONA I NJIHOVA UPOTREBA KAO INHIBITORI PI3
US20100093738A1 (en) *	2006-10-06	2010-04-15	Basf Se	Fungicidal Compounds and Fungicidal Compositions
TW200831498A (en) *	2006-10-13	2008-08-01	Otsuka Pharma Co Ltd	Heterocyclic compound
JP4540700B2 (ja) *	2006-10-13	2010-09-08	大塚製薬株式会社	医薬
WO2008084324A1 (en) *	2007-01-04	2008-07-17	Pfizer Products Inc.	Naphthyridinone compound
JP4785881B2 (ja) *	2007-02-27	2011-10-05	大塚製薬株式会社	医薬
CL2008001002A1 (es)	2007-04-11	2008-10-17	Actelion Pharmaceuticals Ltd	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CN101754761B (zh) *	2007-05-21	2014-06-18	雷维瓦药品公司	基于喹啉酮的非典型抗精神病药的组合物、合成和使用方法
PE20090759A1 (es) *	2007-05-30	2009-07-20	Wyeth Corp	Derivados heteroarilo de benzodioxanos heterociclo-fusionados antidepresivos
US7928111B2 (en) *	2007-06-08	2011-04-19	Senomyx, Inc.	Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors
CN101903380B (zh)	2007-12-18	2013-04-17	埃科特莱茵药品有限公司	5-氨基环甲基-噁唑啶-2-酮衍生物
JP2011529090A (ja)	2008-07-28	2011-12-01	江蘇国華投資有限公司	アラルキルピペリジン（又はピペラジン）誘導体及びその統合失調症治療のための使用
EP2323997B1 (en)	2008-07-31	2017-09-06	Senomyx, Inc.	Processes and intermediates for making sweet taste enhancers
CN102232078B (zh)	2008-12-12	2014-07-16	埃科特莱茵药品有限公司	5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
BRPI1007358A2 (pt) *	2009-01-23	2018-03-06	Takeda Pharmaceutical Company Limited	inibidores de poli (adp-ribose) polimerase (parp)
PT2400968T (pt) *	2009-02-26	2016-12-09	Reviva Pharmaceuticals Inc	Composições, sintese e métodos de utilização dos derivados de arilpiperazína
ES2639065T5 (es) *	2009-06-25	2023-01-30	Alkermes Pharma Ireland Ltd	Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos
AU2010266040B2 (en)	2009-06-25	2015-01-15	Alkermes Pharma Ireland Limited	Prodrugs of NH-acidic compounds
US8536328B2 (en)	2010-05-04	2013-09-17	Alkermes Pharma Ireland Limited	Process for synthesizing oxidized lactam compounds
EP2585066B1 (en)	2010-06-24	2018-09-26	Alkermes Pharma Ireland Limited	Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
WO2012003418A2 (en) *	2010-07-02	2012-01-05	The University Of North Carolina At Chapel Hill	Functionally selective ligands of dopamine d2 receptors
PH12013501489A1 (en)	2010-12-17	2013-08-28	Hoffmann La Roche	Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof
PL2685979T3 (pl)	2011-03-18	2017-02-28	Alkermes Pharma Ireland Limited	Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20
JO3227B1 (ar) *	2011-09-08	2018-03-08	Otsuka Pharma Co Ltd	مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
US9012476B2 (en)	2011-12-08	2015-04-21	IVAX International GmbH	Hydrobromide salt of pridopidine
WO2013088255A1 (en)	2011-12-15	2013-06-20	Alkermes Pharma Ireland Limited	Prodrugs of secondary amine compounds
US9993556B2 (en)	2012-03-19	2018-06-12	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising fatty glycerol esters
CA2867137C (en)	2012-03-19	2020-12-08	Alkermes Pharma Ireland Limited	Pharmaceutical compositions comprising aripiprazole prodrugs and benzyl alcohol
AU2013235519C1 (en)	2012-03-19	2018-04-26	Alkermes Pharma Ireland Limited	Pharmaaceutical compositions comprising fatty acid esters
JP6177875B2 (ja)	2012-04-04	2017-08-09	テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｔｅｒｎａｔｉｏｎａｌＧｍｂＨ	併用療法のための医薬組成物
EP2847193B1 (en) *	2012-05-09	2019-08-07	Sunovion Pharmaceuticals Inc.	Heteroaryl compounds and methods of use thereof
NZ730571A (en)	2012-09-19	2018-12-21	Alkermes Pharma Ireland Ltd	Pharmaceutical compositions having improved storage stability
BR112016021535A8 (pt)	2014-03-20	2021-07-20	Alkermes Pharma Ireland Ltd	kit compreendendo formulações de aripiprazol tendo velocidades de injeção aumentadas útil para o tratamento de uma desordem do sistema nervoso central e uso
CN104785295B (zh) *	2015-03-18	2018-03-06	杭州创培信息科技有限公司	一种高选择性多巴胺铂炭催化剂的制备方法
US9902703B2 (en)	2015-07-01	2018-02-27	Crinetics Pharmaceuticals, Inc.	Somatostatin modulators and uses thereof
CN108697709A (zh)	2015-12-10	2018-10-23	Ptc医疗公司	用于治疗亨廷顿病的方法
CN106242934A (zh) *	2016-07-26	2016-12-21	云南民族大学	一种酮的β‑位C‑H键乙酰氧化合成方法
AU2018282154B2 (en)	2017-06-05	2022-04-07	Ptc Therapeutics, Inc.	Compounds for treating huntington's disease
WO2019005993A1 (en)	2017-06-28	2019-01-03	Ptc Therapeutics, Inc.	METHODS OF TREATING HUNTINGTON'S DISEASE
CN111182898B (zh)	2017-06-28	2024-04-16	Ptc医疗公司	用于治疗亨廷顿氏病的方法
WO2019023278A1 (en)	2017-07-25	2019-01-31	Crinetics Pharmaceuticals, Inc.	MODULATORS OF SOMATOSTATIN AND USES THEREOF
AU2019230014B2 (en)	2018-03-05	2024-11-28	Alkermes Pharma Ireland Limited	Aripiprazole dosing strategy
AU2019232437A1 (en)	2018-03-07	2020-10-08	Bayer Aktiengesellschaft	Identification and use of ERK5 inhibitors
BR112020019373A2 (pt)	2018-03-27	2020-12-29	Ptc Therapeutics, Inc.	Compostos para o tratamento da doença de hutington
WO2020005877A1 (en)	2018-06-27	2020-01-02	Ptc Therapeutics, Inc.	Heteroaryl compounds for treating huntington's disease
IL279688B2 (en)	2018-06-27	2025-01-01	Ptc Therapeutics Inc	Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease
EP3814360B8 (en)	2018-06-27	2024-11-06	PTC Therapeutics, Inc.	Heteroaryl compounds for treating huntington's disease
CN112703193A (zh)	2018-08-07	2021-04-23	弗门尼舍公司	5-取代的4-氨基-1H-苯并[c][1,2,6]噻二嗪2,2-二氧化物及其制剂和用途
PE20211089A1 (es)	2018-08-13	2021-06-14	Hoffmann La Roche	Nuevos compuestos heterociclicos como inhibidores de la monoacilglicerol lipasa
US11066404B2 (en)	2018-10-11	2021-07-20	Incyte Corporation	Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
WO2020168197A1 (en)	2019-02-15	2020-08-20	Incyte Corporation	Pyrrolo[2,3-d]pyrimidinone compounds as cdk2 inhibitors
WO2020180959A1 (en)	2019-03-05	2020-09-10	Incyte Corporation	Pyrazolyl pyrimidinylamine compounds as cdk2 inhibitors
WO2020205560A1 (en)	2019-03-29	2020-10-08	Incyte Corporation	Sulfonylamide compounds as cdk2 inhibitors
WO2020223469A1 (en)	2019-05-01	2020-11-05	Incyte Corporation	N-(1-(methylsulfonyl)piperidin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine derivatives and related compounds as cyclin-dependent kinase 2 (cdk2) inhibitors for treating cancer
US11447494B2 (en)	2019-05-01	2022-09-20	Incyte Corporation	Tricyclic amine compounds as CDK2 inhibitors
PH12022550361A1 (en)	2019-08-14	2023-02-27	Incyte Corp	Imidazolyl pyrimidinylamine compounds as cdk2 inhibitors
MX2022002311A (es)	2019-09-12	2022-03-25	Hoffmann La Roche	Compuestos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inhibidores de monoacilglicerol lipasa (magl).
PE20221905A1 (es)	2019-10-11	2022-12-23	Incyte Corp	Aminas biciclicas como inhibidoras de la cdk2
CN114634479B (zh) *	2020-12-16	2025-02-07	北京盈科瑞创新药物研究有限公司	一种派嗪衍生物、其制备方法及应用
WO2022212538A1 (en) *	2021-03-31	2022-10-06	Blueprint Medicines Corporation	Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof
US11981671B2 (en)	2021-06-21	2024-05-14	Incyte Corporation	Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en)	2021-12-10	2024-05-07	Incyte Corporation	Bicyclic amines as CDK2 inhibitors
JP2025510646A (ja)	2022-03-14	2025-04-15	スラップファーマシューティカルズエルエルシー	多環式化合物
CN116891465A (zh) *	2022-03-30	2023-10-17	苏州旺山旺水生物医药有限公司	一类n-取代的喹啉酮化合物、其制备方法和用途
CN114805081B (zh) *	2022-05-20	2024-09-24	都创(上海)医药开发有限公司	一种基于微通道连续流技术快速制备1-萘胺的方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5649361A (en)	1979-09-28	1981-05-02	Otsuka Pharmaceut Co Ltd	Carbostyril derivative
JP2608788B2 (ja) *	1988-10-31	1997-05-14	大塚製薬株式会社	精神分裂病治療剤
US5006528A (en)	1988-10-31	1991-04-09	Otsuka Pharmaceutical Co., Ltd.	Carbostyril derivatives
JPH07165720A (ja) *	1988-10-31	1995-06-27	Otsuka Pharmaceut Co Ltd	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
HU207310B (en)	1988-12-02	1993-03-29	Pfizer	Process for producing aryl-piperidine derivatives
ES2076253T3 (es)	1989-05-19	1995-11-01	Hoechst Roussel Pharma	N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
US5350747A (en) *	1989-07-07	1994-09-27	Pfizer Inc	Heteroaryl piperazine antipsychotic agents
FI920023A7 (fi) *	1989-07-07	1992-01-03	Pfizer	Heteroaryylipiperatsiiniyhdisteet antipsykootteina
US5032598A (en)	1989-12-08	1991-07-16	Merck & Co., Inc.	Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
AU645681B2 (en) *	1991-05-02	1994-01-20	John Wyeth & Brother Limited	Piperazine derivatives
NZ240863A (en)	1991-09-11	1995-04-27	Mcneilab Inc	Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
US5206366A (en) *	1992-08-26	1993-04-27	Pfizer Inc.	Process for preparing aryl piperazinyl-heterocyclic compounds
BR9307664A (pt)	1992-12-17	1999-06-29	Pfizer	Pirazóis substituídos como antagonistas
EP0674641B1 (en)	1992-12-17	1999-03-03	Pfizer Inc.	Pyrrolopyrimidines as crf antagonists
WO1994013643A1 (en)	1992-12-17	1994-06-23	Pfizer Inc.	Pyrazoles and pyrazolopyrimidines having crf antagonist activity
TW444018B (en)	1992-12-17	2001-07-01	Pfizer	Pyrazolopyrimidines
TW336932B (en)	1992-12-17	1998-07-21	Pfizer	Amino-substituted pyrazoles
FR2699918B1 (fr) *	1992-12-30	1995-03-17	Pf Medicament	Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments.
JPH07247271A (ja) *	1994-01-21	1995-09-26	Otsuka Pharmaceut Co Ltd	３，４−ジヒドロカルボスチリル誘導体
FR2731222A1 (fr)	1995-03-02	1996-09-06	Pf Medicament	Nouveaux derives de piperazine aminoindoles cycliques, leur procede de preparation et leur utilisation a titre de medicaments
JP2987484B2 (ja) *	1995-03-16	1999-12-06	大塚製薬株式会社	カルボスチリル誘導体の製造方法
JP2900130B2 (ja) *	1995-03-16	1999-06-02	大塚製薬株式会社	カルボスチリル誘導体及び該誘導体を含有する精神分裂病治療剤
IL117923A (en)	1995-05-03	2000-06-01	Warner Lambert Co	Anti-cancer pharmaceutical compositions containing polysubstituted pyrido¬2,3-d¾pyrimidine derivatives and certain such novel compounds
US6114334A (en)	1995-07-13	2000-09-05	Knoll Aktiengesellschaft	Piperazine derivatives as therapeutic agents
WO1997014419A1 (en)	1995-10-20	1997-04-24	Flora Inc.	Transdermal delivery of alpha adrenoceptor blocking agents
JPH09241161A (ja)	1996-03-08	1997-09-16	Nippon Shinyaku Co Ltd	医薬
US5912256A (en)	1996-06-20	1999-06-15	Eli Lilly And Company	Compounds having effects on serotonin-related systems
US5945422A (en)	1997-02-05	1999-08-31	Warner-Lambert Company	N-oxides of amino containing pyrido 2,3-D! pyrimidines
US6498163B1 (en)	1997-02-05	2002-12-24	Warner-Lambert Company	Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
FR2761071B1 (fr)	1997-03-20	1999-12-03	Synthelabo	Derives de quinolein-2(1h)-one et de dihydroquinolein-2(1h)- one, leur preparation et leur application en therapeutique
FR2769912B1 (fr)	1997-10-16	2000-03-10	Pf Medicament	Nouveaux derives de la 3-oxo- (2h)-1,2,4 triazine leur preparation et leur application en therapeutique humaine
DE19747063A1 (de) *	1997-10-24	1999-04-29	Basf Ag	3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung
US6267784B1 (en)	1998-05-01	2001-07-31	Benz Research And Development Corporation	Intraocular lens and haptics made of a copolymer
US6844344B2 (en)	1999-12-20	2005-01-18	Eli Lilly And Company	Benzofuran derivatives
DE10041574A1 (de)	2000-08-24	2002-03-07	Merck Patent Gmbh	Chromenonderivate
AU2002243394A1 (en)	2000-11-16	2002-06-24	Wyeth	Aryloxy piperidinyl derivatives for the treatment of depression
GB0101577D0 (en)	2001-01-22	2001-03-07	Smithkline Beecham Plc	Compounds
AR032641A1 (es)	2001-01-29	2003-11-19	Otsuka Pharma Co Ltd	Agonista de subtipo de receptor 5-ht 1a.
US20040248883A1 (en)	2001-06-29	2004-12-09	Mario Rottlander	Novel heteroaryl derivatives, their preparation and use
GB0227240D0 (en)	2002-11-21	2002-12-31	Glaxo Group Ltd	Compounds
TW200507841A (en)	2003-03-27	2005-03-01	Glaxo Group Ltd	Antibacterial agents
US7160888B2 (en) *	2003-08-22	2007-01-09	Warner Lambert Company Llc	[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia

2004
- 2004-07-28 US US10/900,210 patent/US7160888B2/en not_active Expired - Fee Related
- 2004-08-13 EP EP04744287A patent/EP1660497A1/en not_active Withdrawn
- 2004-08-13 ME MEP-453/08A patent/MEP45308A/xx unknown
- 2004-08-13 AU AU2004266191A patent/AU2004266191B2/en not_active Ceased
- 2004-08-13 KR KR1020077009877A patent/KR100801794B1/ko not_active Expired - Fee Related
- 2004-08-13 NZ NZ545078A patent/NZ545078A/en unknown
- 2004-08-13 RS RSP-2006/0129A patent/RS20060129A/sr unknown
- 2004-08-13 BR BRPI0413860-0A patent/BRPI0413860A/pt not_active IP Right Cessation
- 2004-08-13 CN CNB2004800241500A patent/CN100422181C/zh not_active Expired - Fee Related
- 2004-08-13 GE GEAP20049246A patent/GEP20084447B/en unknown
- 2004-08-13 CA CA2538915A patent/CA2538915C/en not_active Expired - Fee Related
- 2004-08-13 UA UAA200601890A patent/UA82541C2/uk unknown
- 2004-08-13 OA OA1200600052A patent/OA13238A/en unknown
- 2004-08-13 KR KR1020067003621A patent/KR100765668B1/ko not_active Expired - Fee Related
- 2004-08-13 WO PCT/IB2004/002665 patent/WO2005019215A1/en not_active Ceased
- 2004-08-13 JP JP2006523707A patent/JP4034811B2/ja not_active Expired - Fee Related
- 2004-08-13 AP AP2006003525A patent/AP2006003525A0/xx unknown
- 2004-08-13 EA EA200600294A patent/EA009645B1/ru not_active IP Right Cessation
- 2004-08-13 MX MXPA06002070A patent/MXPA06002070A/es active IP Right Grant
- 2004-08-18 PE PE2004000796A patent/PE20051039A1/es not_active Application Discontinuation
- 2004-08-20 NL NL1026892A patent/NL1026892C2/nl not_active IP Right Cessation
- 2004-08-20 HN HN2004000319A patent/HN2004000319A/es unknown
- 2004-08-20 MY MYPI20043415A patent/MY140693A/en unknown
- 2004-08-20 PA PA20048609701A patent/PA8609701A1/es unknown
- 2004-08-20 TW TW093125196A patent/TWI298327B/zh active
- 2004-08-20 AR ARP040103006A patent/AR045386A1/es not_active Application Discontinuation
2005
- 2005-01-13 GT GT200500007A patent/GT200500007A/es unknown
2006
- 2006-01-20 NO NO20060324A patent/NO20060324L/no not_active Application Discontinuation
- 2006-01-26 IS IS8267A patent/IS8267A/is unknown
- 2006-01-30 IL IL173439A patent/IL173439A0/en unknown
- 2006-02-10 CU CU20060028A patent/CU23464B7/es not_active IP Right Cessation
- 2006-02-21 ZA ZA200601526A patent/ZA200601526B/en unknown
- 2006-02-22 EC EC2006006391A patent/ECSP066391A/es unknown
- 2006-02-22 MA MA28828A patent/MA28003A1/fr unknown
- 2006-02-22 CR CR8254A patent/CR8254A/es unknown
- 2006-02-22 TN TNP2006000063A patent/TNSN06063A1/en unknown
- 2006-08-24 US US11/466,822 patent/US20060287309A1/en not_active Abandoned
- 2006-08-24 US US11/466,828 patent/US20060287310A1/en not_active Abandoned
2008
- 2008-03-27 CR CR9834A patent/CR9834A/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
AP2006003525A0 (en)	2006-02-28
EA009645B1 (ru)	2008-02-28
MA28003A1 (fr)	2006-07-03
IL173439A0 (en)	2006-06-11
WO2005019215A1 (en)	2005-03-03
KR100765668B1 (ko)	2007-10-10
OA13238A (en)	2006-12-13
CR9834A (es)	2008-04-21
TNSN06063A1 (en)	2007-10-03
CU23464B7 (es)	2009-12-17
MXPA06002070A (es)	2006-05-19
GT200500007A (es)	2005-10-24
US20050043309A1 (en)	2005-02-24
AU2004266191B2 (en)	2009-11-26
CA2538915C (en)	2010-06-15
NZ545078A (en)	2009-09-25
KR100801794B1 (ko)	2008-02-05
US7160888B2 (en)	2007-01-09
JP2007503386A (ja)	2007-02-22
US20060287310A1 (en)	2006-12-21
CR8254A (es)	2006-10-17
AU2004266191A1 (en)	2005-03-03
HN2004000319A (es)	2010-06-09
TWI298327B (en)	2008-07-01
AR045386A1 (es)	2005-10-26
CN100422181C (zh)	2008-10-01
BRPI0413860A (pt)	2006-10-24
NO20060324L (no)	2006-05-18
ECSP066391A (es)	2006-08-30
CN1839134A (zh)	2006-09-27
JP4034811B2 (ja)	2008-01-16
MEP45308A (en)	2011-02-10
PE20051039A1 (es)	2005-12-12
EP1660497A1 (en)	2006-05-31
GEP20084447B (en)	2008-08-10
EA200600294A1 (ru)	2006-08-25
KR20060071404A (ko)	2006-06-26
KR20070053364A (ko)	2007-05-23
US20060287309A1 (en)	2006-12-21
MY140693A (en)	2010-01-15
PA8609701A1 (es)	2005-05-24
NL1026892C2 (nl)	2005-11-21
TW200524938A (en)	2005-08-01
NL1026892A1 (nl)	2005-02-28
RS20060129A (sr)	2008-06-05
UA82541C2 (uk)	2008-04-25
CA2538915A1 (en)	2005-03-03
ZA200601526B (en)	2007-04-25
HK1091815A1 (zh)	2007-01-26

Publication	Publication Date	Title
IS8267A (is)	2006-01-26	[1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa
NO20042147L (no)	2004-05-25	Heterocykliske forbindelser og fremgangsmater for anvendelse derav
DE502004002801D1 (de)	2007-03-15	Bohrlochbehandlungsmittel, enthaltend ethercarbonsäuren
IS7710A (is)	2005-02-24	Heterósýklísk setin píperasín til notkunar við meðferð á geðklofa
NO20053771D0 (no)	2005-08-08	Ringromsfluider og fremgangsmater for plassering av de samme
DE60308431D1 (de)	2006-11-02	Geschäumte Säurebehandlungsflüssigkeit
IL173398A0 (en)	2006-06-11	Pyridyl derivatives and their use as therapeutic agents
NO20053974D0 (no)	2005-08-25	Tienopyrimidinforbindelser og anvendelse derav.
GB0109537D0 (en)	2001-06-06	Well treatment fluids and methods for the use thereof
IS7913A (is)	2005-06-23	Pýrasóló[3,4-b]pýridín efnasambönd, og notkun þeirra sem fosfórdíesterasa hindrar
NO20051503D0 (no)	2005-03-21	Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
IS8142A (is)	2005-11-23	Læknislyf gagnleg til meðferðar á verkjum
IS8071A (is)	2005-10-13	Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
AP2004002997A0 (en)	2004-03-31	Heterocyclic compounds for use in the treatment ofdisorders of the urinary tract.
PL1638628T3 (pl)	2014-05-30	Urządzenie do obróbki krwi
IS7444A (is)	2004-09-13	Morfólínýl-þvagefna afleiður til notkunar við meðhöndlun á bólguvaldandi sjúkdómum
NO20053593D0 (no)	2005-07-22	Arylalkylkarbamat-derivater, fremgangsmate og anvendelse derav i terapi
IS7858A (is)	2005-05-23	Samsetning til notkunar í meðferð á athyglisbresti með ofvirkni (ADHD)
DK1678085T3 (da)	2010-08-23	Fluidbehandlingsindretning
DK1589973T4 (da)	2013-04-08	Formulering og fremgangsmåder til behandling af thrombocytæmi
IS7275A (is)	2004-05-21	Samsetning fyrir hollegg og notkun á henni
NO20053809D0 (no)	2005-08-12	Diarylmetylindenpiperidinderivater,fremgangsmate for fremstilling derav, og anvendelse derav
NO20054535D0 (no)	2005-10-03	Bifunksjonelle heterocykliske forbindelser og fremgangsmater for fremstilling og anvendelse av samme
IS8383A (is)	2006-03-29	Nýjar afleiður af 4a,5,9,10,11,12-hexahýdróbensófúró[3a,3,2][2]-bensasepín, aðferð við framleiðslu þeirra og notkun þeirra við framleiðslu á lyfjum
NO20033120L (no)	2003-09-11	2-arylimino-2,3-dihydrotiazolderivater, fremgangsmåter for fremstilling derav og terapeutisk anvendelse derav